Lexeo Therapeutics Announces LX2020 Interim Clinical Results and Q3 Financials
LXEO Lexeo Therapeutics Inc
$2.87 -1.37%
View chart & analysis → - 1Non-sustained ventricular tachycardia decreased by an average of 80% in the high-dose group.
- 2Lexeo recorded a net loss of $38.3 million in the third quarter of 2026.
- 3Lexeo held cash and investment balances of $219.1 million as of the end of September.
So what's the key point?
Lexeo Therapeutics' drug trial results showed an 80 percent reduction in irregular heartbeats. The company reported a loss of $38.3 million but still has available funds.
Source InvestorsHub +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.